Development of genetically engineered CD4 super(+) and CD8 super(+) T cells expressing TCRs specific for a M. tuberculosis 38-kDa antigen

• Published in: Journal of molecular medicine (Berlin, Germany) Germany), 2011-09, Vol.89 (9), p.903-913
• Main Authors: Luo, Wei, Zhang, Xiao-Bing, Huang, Yong-Ta, Hao, Pei-Pei, Jiang, Zhen-Min, Wen, Qian, Zhou, Ming-Qian, Jin, Qi, Ma, Li
• Format: Article
• Language: English
• Subjects: Adoptive transfer; Amino acids; Antigen (tumor-associated); CD4 antigen; CD8 antigen; Cell surface; Effector cells; Genetic engineering; Histocompatibility antigen HLA; Immunity (cell-mediated); Immunotherapy; Lymphocytes T; Mycobacterium tuberculosis; Pathogens; T-cell receptor; Tuberculosis; Tumors
• ISSN: 0946-2716; 1432-1440
• DOI: 10.1007/s00109-011-0760-4

Cell-mediated immunity is critical to the clearance of Mycobacterium tuberculosis due to the primarily intracellular niche of this pathogen. Adoptive transfer of M. tuberculosis-specific effector T cells has been shown to confer immunity to M. tuberculosis-infected recipients resulting in M. tuberculosis clearance. However, it is difficult to generate sufficient numbers of M. tuberculosis antigen-specific T cells in a short time. Recent studies have developed T cell receptor (TCR) gene-modified T cells that allow for the rapid generation of large numbers of antigen-specific T cells. Many TCRs that target various tumor and viral antigens have now been isolated and shown to have functional activity. Nevertheless, TCRs specific for intracellular bacterial antigens (including M. tuberculosis antigens) have yet to be isolated and their functionality confirmed. We isolated M. tuberculosis 38-kDa antigen-specific HLA class I and class II-restricted TCRs and modified the TCR gene C regions by substituting nine amino acids with their murine TCR homologs (minimal murinization). Results showed that both wild-type and minimal murinized TCR genes were successfully cloned into retroviral vectors and transduced into primary CD4 super(+) and CD8 super(+) T cells and displayed anti-M. tuberculosis activity. As expected, minimal murinized TCRs displayed higher cell surface expression levels and stronger anti-M. tuberculosis activity than wild-type TCRs. To the best of our knowledge, this is the first report describing TCRs targeting M. tuberculosis antigens and this investigation provides the basis for future TCR gene-based immunotherapies that can be designed for the treatment of immunocompromised M. tuberculosis-infected patients.